Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst Upgrade

Astria Therapeutics, Inc. (NASDAQ:ATXS) shares gapped up before the market opened on Thursday after Oppenheimer raised their price target on the stock from $26.00 to $28.00. The stock had previously closed at $10.61, but opened at $11.53. Oppenheimer currently has an outperform rating on the stock. Astria Therapeutics shares last traded at $10.67, with a volume of 27,733 shares traded.

Several other research analysts have also recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. TD Cowen assumed coverage on Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 target price for the company. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Friday, September 27th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.60.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ATXS. Quest Partners LLC lifted its position in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 2,861 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Astria Therapeutics in the 3rd quarter valued at approximately $155,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Astria Therapeutics during the 1st quarter valued at approximately $200,000. Finally, Hsbc Holdings PLC acquired a new position in Astria Therapeutics during the 2nd quarter worth approximately $171,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Trading Up 0.6 %

The firm has a market capitalization of $602.05 million, a price-to-earnings ratio of -4.61 and a beta of 0.71. The stock’s 50-day moving average is $11.46 and its 200-day moving average is $10.61.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, equities research analysts anticipate that Astria Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.